We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Join us at CAR-TCR Summit 2024 to discover the effectiveness of ProtoNK cells on cancer cells, strategies to overcome cell therapy limitations, and how Shenandoah CTGrade GMP Recombinant Proteins can enhance your immunotherapy. FUJIFILM Irvine Scientific invites you to visit us at Booth #10 and attend the sponsored presentation by HebeCell founder and Chief Scientific Officer, Allen Feng, PhD.
Presentation Details
Title: Hematopoiesis in Bioreactor and Translation of ProtoNK Platform
Speaker: Allen (Qiang) Feng, PhD, Founder and Chief Scientific Officer of HebeCell Corp.
Date: September 18, 2024
Time: 4:40 PM – 5:10 PM EDT
Location: Plenary Sessions, Main Stage
HebeCell: Mimicking Natural Hematopoiesis Driven by Growth Factors from FUJIFILM Irvine Scientific
- Discover how successful translation of PSC-derived cell manufacturing will change the market landscape of recombinant proteins
- See compelling results for HebeCell’s ProtoNK Platform, demonstrating how it can produce high quality cells at industry scale that meet PSC-derived cell manufacturing requirements
- Learn about CTGrade GMP Recombinant Proteins and how they facilitate over a 40% increase in total NK yield compared to another supplier for a total cell count of nearly 968 million cells
Poster Details
Title: Demonstrating Key Processes of the T Cell Therapy Workflow in Chemically Defined Media
Maintain robust T cell functionality in response to antigenic stimulation using a PRIME-XV media and CTGrade GMP Recombinant Proteins enabled workflow that streamlines the manufacturing process by eliminating the need for a post-thaw wash step.